A recent study has shed light on the high effectiveness of misoprostol-alone regimens for self-managed abortion, challenging previous assumptions. The study found that misoprostol alone can effectively terminate the pregnancy of <7 weeks duration in 24 hours.
The study results were published in JAMA Network Open.
The World Health Organization recommends two medication regimens for abortion: mifepristone combined with misoprostol and misoprostol alone. Both are effective with low complication rates. Misoprostol alone is considered less effective (around 80% vs. 95%) and is recommended when mifepristone is unavailable. Misoprostol is favored for self-managed abortion due to its low cost, accessibility, and ease of use. However, data on the effectiveness of endorsed misoprostol-alone protocols are limited. This study aims to assess the safety and effectiveness of misoprostol-alone abortion, providing insights into physical experiences and healthcare-seeking behavior, with implications for clinical practice and policy.

Also Read: Rh testing or immunoglobulin administration following induced first-trimester abortion not necessary: JAMA
The study, which included participants aged 13 and older with no contraindications to medication abortion, focused on those who used misoprostol alone and completed a baseline and two follow-up surveys. The analysis, performed between January 2022 and September 2023, yielded compelling results.
Effectiveness was the primary outcome measured in the study, with complete abortion without procedural intervention as the goal. Safety was the secondary outcome where self-report of experiencing warning signs indicative of a potential complication and by medical treatment. length of bleeding and cramping, time to expulsion, and experience of adverse effects were the other outcomes.
Furthermore, the study delved into the safety of the misoprostol-alone regimen.

Findings:
Out of the 1352 participants in the study, 637 utilized misoprostol-alone regimens for abortion and were considered in the analysis.
The majority were from Nigeria (591, 92.8%), with a smaller number from Southeast Asia (45, 7.1%), and just one from Argentina (0.2%).
Among these, 384 (60.2%) were aged 20-29 years, 317 (49.8%) had pregnancies of less than 7 weeks, and 205 (32.2%) had pregnancies between 7 and less than 9 weeks.
At the final follow-up, which occurred approximately 22 days after taking the medication (with an interquartile range of 21-26 days), a significant 625 participants (98.1%, 95% confidence interval: 96.7%-98.9%) achieved a complete abortion without requiring any medical intervention.
A mere 6 participants (0.9%, 95% confidence interval: 0.4%-2.1%) reported potential adverse events.
Most participants experienced bleeding for a relatively short duration, with a median of 4 days (interquartile range: 3-6 days), and successfully expelled their pregnancies within 24 hours of commencing the abortion process, with a median time of 12 hours (interquartile range: 9-15 hours).
The common side effects observed included nausea, reported by 335 participants (52.6%), fever in 232 (36.4%), and diarrhea in 181 (28.4%).
Also Read: Vaginal Bleeding During Pregnancy Linked to Spontaneous Abortion Risk
In summary, this study's findings suggest that misoprostol alone is a highly effective and safe method for self-managed abortion, challenging preconceived notions about its efficacy. This could have significant implications for reproductive healthcare and access to safe abortion services, offering hope and choice to individuals seeking safe and effective pregnancy termination methods. This information is crucial for healthcare providers and organizations that offer abortion services, as it may inform the development of protocols and guidelines for medication abortion. It can also influence policies and regulations related to access to medication abortion, particularly in regions where abortion services are restricted or inaccessible.
Further reading: Jayaweera R, Egwuatu I, Nmezi S, et al. Medication Abortion Safety and Effectiveness With Misoprostol Alone. JAMA Netw Open. 2023;6(10):e2340042. doi:10.1001/jamanetworkopen.2023.40042